ES2539812T3 - Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos - Google Patents

Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos Download PDF

Info

Publication number
ES2539812T3
ES2539812T3 ES08723922.4T ES08723922T ES2539812T3 ES 2539812 T3 ES2539812 T3 ES 2539812T3 ES 08723922 T ES08723922 T ES 08723922T ES 2539812 T3 ES2539812 T3 ES 2539812T3
Authority
ES
Spain
Prior art keywords
prame
same
immunogenic compositions
peptides derived
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08723922.4T
Other languages
English (en)
Inventor
Jan Kessler
Marieke Griffioen
Cornelis Johannes Maria Melief
Jan Wouter Drijfhout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Original Assignee
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leids Universitair Medisch Centrum LUMC filed Critical Leids Universitair Medisch Centrum LUMC
Application granted granted Critical
Publication of ES2539812T3 publication Critical patent/ES2539812T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464489—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

Péptido con una longitud de no más de 50 aminoácidos y que comprende al menos 33 aminoácidos contiguos de la secuencia de aminoácidos de la proteína de PRAME humana, donde el péptido comprende al menos un epítopo de HLA de clase II y al menos un epítopo de HLA de clase I de la secuencia de aminoácidos de la proteína de PRAME humana y donde el péptido comprende SEC ID nº 6.

Description

18
19
23
24
25
26
27
28
29
30
31
ES08723922.4T 2007-03-26 2008-03-26 Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos Active ES2539812T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07104893 2007-03-26
EP07104893 2007-03-26
PCT/NL2008/050171 WO2008118017A2 (en) 2007-03-26 2008-03-26 Prame derived peptides and immunogenic compositions comprising these

Publications (1)

Publication Number Publication Date
ES2539812T3 true ES2539812T3 (es) 2015-07-06

Family

ID=38267662

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08723922.4T Active ES2539812T3 (es) 2007-03-26 2008-03-26 Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos

Country Status (8)

Country Link
US (3) US8492514B2 (es)
EP (3) EP2462947B1 (es)
JP (2) JP5649952B2 (es)
CN (2) CN101687022B (es)
AU (1) AU2008230240B2 (es)
CA (2) CA2996732C (es)
ES (1) ES2539812T3 (es)
WO (1) WO2008118017A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062634A2 (en) * 2009-11-18 2011-05-26 Mannkind Corporation Monoclonal antibodies and diagnostic uses thereof
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
US9758829B2 (en) 2012-06-22 2017-09-12 Htg Molecular Diagnostics, Inc. Molecular malignancy in melanocytic lesions
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
US10188712B2 (en) * 2013-07-30 2019-01-29 Biontech Ag Tumor antigens for determining cancer therapy
MX2017008406A (es) 2014-12-23 2018-04-24 Anne Brimble Margaret Conjugados de aminoacidos y peptidos y sus usos.
WO2016191246A2 (en) 2015-05-22 2016-12-01 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a prame peptide
EP3112375A1 (en) * 2015-07-03 2017-01-04 Ludwig-Maximilians-Universität München Antigenic peptides for the diagnosis, therapy monitoring and/or treatment of psoriasis vulgaris
CN106519019B (zh) * 2015-11-06 2018-07-03 广东香雪精准医疗技术有限公司 识别prame抗原的tcr
CN106831978B (zh) * 2015-12-04 2020-05-26 中国科学院广州生物医药与健康研究院 识别prame抗原的t细胞受体
IL298653A (en) 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against several types of cancer
JP7161404B2 (ja) 2016-02-26 2022-10-26 オークランド ユニサービシーズ リミティド アミノ酸及びペプチド接合体及び接合方法
CN106699874B (zh) * 2016-03-29 2018-06-05 广东香雪精准医疗技术有限公司 识别prame抗原短肽的t细胞受体
CN107266552B (zh) * 2016-03-30 2022-02-08 香雪生命科学技术（广东）有限公司 源自于prame的肿瘤抗原短肽
WO2017220463A1 (en) 2016-06-20 2017-12-28 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
CN108203459A (zh) * 2016-12-19 2018-06-26 广东香雪精准医疗技术有限公司 源自于prame的肿瘤抗原短肽
CN108203460B (zh) * 2016-12-19 2021-10-08 香雪生命科学技术（广东）有限公司 衍生自肿瘤抗原prame的短肽
CN108264550B (zh) * 2017-01-04 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别源自于prame抗原短肽的tcr
NL2018803B1 (en) 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds
CN108929378B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原的t细胞受体及编码该受体的核酸
GB201709866D0 (en) * 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
WO2019025433A1 (en) * 2017-08-02 2019-02-07 Idp Discovery Pharma, S.L. PEPTIDES WITH ANTICANCER ACTIVITY
CN109400696B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原短肽的tcr
ES2938900T3 (es) * 2017-12-13 2023-04-17 Inovio Pharmaceuticals Inc Vacunas contra el cáncer dirigidas al PRAME y usos de las mismas
CA3223357A1 (en) 2021-07-12 2023-01-19 Brigitte Elisa Anna Burm Improved substance quantification in complex mixtures
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
WO2024079311A1 (en) 2022-10-13 2024-04-18 Isa Pharmaceuticals B.V. Modified long peptides suitable for use in immunisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
WO1999061065A1 (en) 1998-05-23 1999-12-02 Leiden University Medical Center Cd40 binding molecules and ctl peptides for treating tumors
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US20020049312A1 (en) * 2000-05-23 2002-04-25 Turner C. Alexander Noel human thrombospondin-like proteins and polynucleotides encoding the same
FR2804117B1 (fr) 2000-01-21 2004-08-20 Bio Merieux Procede d'isolement de proteines et/ou d'acides nucleiques, complexes de particules et de proteines et/ou d'acides nucleiques, reactif et applications
EP1118860A1 (en) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
ES2519043T3 (es) 2000-12-08 2014-11-06 Academisch Ziekenhuis Leiden Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2003084467A2 (en) * 2002-04-01 2003-10-16 Euro-Celtique S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
CA2496888A1 (en) * 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
ES2456666T3 (es) * 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
ATE476196T1 (de) * 2003-06-17 2010-08-15 Mannkind Corp Zusammensetzung zur auslösung, verbesserung und erhaltung von immunantworten gegen mhc-klasse-i- beschränkte epitope, für prophylaktische oder therapeutische zwecke
US7340702B2 (en) * 2003-07-23 2008-03-04 Cadence Design Systems, Inc. Method and apparatus for induction proof
AU2005265182B2 (en) 2004-06-17 2012-06-21 Mannkind Corporation Epitope analogs
EP2371851A3 (en) * 2005-06-17 2012-08-01 Mannkind Corporation Epitope analogues
AU2006259220C1 (en) * 2005-06-17 2013-05-16 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma

Also Published As

Publication number Publication date
JP5985551B2 (ja) 2016-09-06
EP2125005A2 (en) 2009-12-02
CN106220721B (zh) 2020-04-07
CN101687022A8 (zh) 2016-08-24
US20100120683A1 (en) 2010-05-13
CN101687022B (zh) 2016-09-07
WO2008118017A3 (en) 2008-12-31
US20140348862A1 (en) 2014-11-27
JP5649952B2 (ja) 2015-01-07
EP3533461A2 (en) 2019-09-04
JP2014240407A (ja) 2014-12-25
CA2681132A1 (en) 2008-10-02
US10450356B2 (en) 2019-10-22
JP2010522748A (ja) 2010-07-08
CA2996732C (en) 2020-10-27
CN101687022A (zh) 2010-03-31
CA2996732A1 (en) 2008-10-02
EP2462947B1 (en) 2019-03-13
CA2681132C (en) 2018-05-01
US20160333065A1 (en) 2016-11-17
AU2008230240B2 (en) 2012-09-13
EP2462947A1 (en) 2012-06-13
US8492514B2 (en) 2013-07-23
AU2008230240A1 (en) 2008-10-02
US9441025B2 (en) 2016-09-13
WO2008118017A2 (en) 2008-10-02
CN106220721A (zh) 2016-12-14
EP3533461A3 (en) 2019-12-18
EP2125005B1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
ES2531142T3 (es) Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
EA200870237A1 (ru) Последовательности пептидов и композиции
RS53872B1 (en) NEW AND POWERFUL CLASS II MHC PEPTIDES DERIVATED FROM SURVIVINE AND UNAURANTS
ES2571879T3 (es) Moléculas de una sola cadena de TNFSF
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
AR082235A2 (es) Composicion de hepcidina, metodos para identificar compuestos que se unen a esta y peptidos analogos
ES2668967T3 (es) Inmunógenos de Escherichia coli con solubilidad mejorada
ES2530777T3 (es) Vacunas peptídicas para cánceres que expresan antígenos asociados a tumores
PE20100253A1 (es) Mutantes de fgf21
ES2528133T3 (es) Péptidos y composiciones para prevención de la adhesión celular, y métodos para utilizar los mismos
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
NZ593833A (en) Extended recombinant polypeptides and compositions comprising same
ES2616258T3 (es) Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna
ES2534752T3 (es) Nuevo péptido antigénico contra el cáncer y utilización del mismo
CR9452A (es) Agentes terapeuticos a base de peptidos de toxinas
RS54133B1 (en) ANTI-IL-6 ANTIBODIES, PREPARATIONS, PREPARATION AND USE PROCEDURES
ES2507094T3 (es) Proteína específica del timo
ES2160485B1 (es) Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
ES2530457T3 (es) Secuencias peptídicas, su forma ramificada y uso de estas para aplicaciones antimicrobianas